Xbrane Biopharma
Xbrane Biopharma is establishing a new biotech lab at Campus Solna (MFN)
- Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) has entered into an agreement with Akademiska Hus for the lease of new premises on Campus Solna.
- In March 2021, Xbrane will establish a new development lab for biosimilars with significantly expanded capacity compared to the current and will at the same time move its headquarter to Campus Solna.
- From the second quarter of 2021 and onwards, Xbrane will further expand its portfolio and initiate development of additional biosimilar candidates on blockbuster biologics with patent expiration during this decade.
Xbrane has expanded significantly in recent years and successfully advanced its leading biosimilar candidate Xlucane (Lucentis® biosimilar) into phase III and entered into strategic partnerships with STADA, a European biosimilar specialist, and Bausch + Lomb, a leading global eye product and pharmaceutical company. In addition, Xbrane has three additional pre-clinical biosimilar candidates under development that address total originator sales of just under SEK 100 billion. In its team of over 40 experts in various areas of drug development, Xbrane has the expertise required to take biosimilars all the way to market approval in Europe and the United States. Furthermore, with Xlucane, Xbrane has validated its patented platform technology, which provides a significant cost advantage over competing systems and with another seven patent applications in 2020 worked actively with the IP protection of the platform.
To take the next step in the company's ambition to become a leading global biosimilar developer and broaden its biosimilar portfolio, the company has entered into an agreement with Akademiska Hus to expand its operations to larger premises with better technical conditions at Campus Solna in March 2021. Xbrane will move its headquarter and establish a development lab with significantly expanded capacity and expect to, from second quarter 2021 and onwards, be able to start development of additional biosimilar candidates on blockbuster biologics with patent expiration during this decade. This expansion includes the expansion of capacity where Xbrane develops the production processes for both mammalian cell- and E. coli-based biosimilars as well as the advanced analysis capacity needed during the development of biosimilars. Xbrane, together with other leading Swedish Life Science companies, will form part of a larger cluster at Campus Solna focusing on development and innovation in the Life Science sector.
“In order to fully leverage our platform technology and achieve our goal of becoming a leading global biosimilar developer, it is time for us to expand our capacity and broaden our portfolio. We have the technology and know-how and want to use it to develop more biosimilars on blockbuster biologics with patent expiration during this decade. The premises at Campus Solna suit us well for this purpose.”, Comments Martin Åmark, CEO.
Contacts
Martin Åmark, CEO/ IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.